November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
In each outcome, we combined the results of the two drug arms [33]
20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group
Vegetables offer vitamins, minerals, hydration, and balanced digestive support
People who had anti-nausea strategies, small meal containers, and hydration reminders in place before symptoms peaked were far more likely to complete the full treatment course
Some vials dissolve in under 30 seconds